Literature DB >> 12228116

Alosetron for irritable bowel syndrome.

Michel Lièvre.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12228116      PMCID: PMC1124090          DOI: 10.1136/bmj.325.7364.555

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  2 in total

1.  Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.

Authors:  M Camilleri; A R Northcutt; S Kong; G E Dukes; D McSorley; A W Mangel
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

Review 2.  Irritable bowel, irritable body, or irritable brain?

Authors:  M J Farthing
Journal:  BMJ       Date:  1995-01-21
  2 in total
  8 in total

1.  Bias in research and conflict of interest: why should we care?

Authors:  H P Dietz
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2006-11-21

2.  The good old drugs!

Authors:  I Ralph Edwards
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

3.  Management of irritable bowel syndrome in primary care: feasibility randomised controlled trial of mebeverine, methylcellulose, placebo and a patient self-management cognitive behavioural therapy website. (MIBS trial).

Authors:  Hazel A Everitt; Rona E Moss-Morris; Alice Sibelli; Laura Tapp; Nicholas S Coleman; Lucy Yardley; Peter W Smith; Paul S Little
Journal:  BMC Gastroenterol       Date:  2010-11-18       Impact factor: 3.067

Review 4.  Alosetron in irritable bowel syndrome: strategies for its use in a common gastrointestinal disorder.

Authors:  Anthony Lembo; H Christian Weber; Francis A Farraye
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 5.  Evaluation of drug treatment in irritable bowel syndrome.

Authors:  Nicholas J Talley
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

Review 6.  Role of antispasmodics in the treatment of irritable bowel syndrome.

Authors:  Anita Annaházi; Richárd Róka; András Rosztóczy; Tibor Wittmann
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

Review 7.  Reassessing the benefits and risks of alosetron: what is its place in the treatment of irritable bowel syndrome?

Authors:  Viola Andresen; Stephan Hollerbach
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

8.  Functional Somatic Syndromes: Emerging Biomedical Models and Traditional Chinese Medicine.

Authors:  Steven Tan; Kirsten Tillisch; Emeran Mayer
Journal:  Evid Based Complement Alternat Med       Date:  2004-06-01       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.